5-Amino-1MQ
Also known as: 5A1MQ, 5-Amino-1-methylquinolinium, 5-amino-1-methylquinolinium
3 notable studies · 3 references
TLDR
5-Amino-1MQ is an experimental small-molecule NNMT inhibitor that has reduced adiposity and improved insulin sensitivity, glucose regulation, and fatty-liver pathology in obese mice, but controlled human efficacy and safety evidence is currently lacking.
Research Supports
- Studied for its role in obesity and body-fat accumulation via NNMT inhibition
- Investigated for effects on insulin sensitivity and glucose tolerance
- Examined for effects on fatty-liver pathology
- Studied in relation to NAD+ and SAM (methyl-donor) metabolism
Observations Reported in Research
- Dose-dependently limited body-weight and fat-mass gain over 28 days in diet-induced obese mice (2024 study)
- Reduced liver weight, hepatic triglycerides, and steatosis in obese mice
- Reduced body weight and white-adipose mass without reducing food intake in diet-induced obese mice (Neelakantan et al., 2018)
- Combined with dietary change, produced greater adiposity reduction than diet alone and altered gut microbiome in obese mice
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor; experimental metabolic compound
5-Amino-1MQ is an experimental small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). It is commonly discussed in research-compound circles for: • Fat loss • Obesity • Metabolic health • Insulin sensitivity • NAD+ metabolism • Fatty liver • Energy metabolism The scientific rationale is legitimate. NNMT is an enzyme involved in nicotinamide metabolism and cellular methylation chemistry, and increased NNMT expression has been associated with obesity and metabolic dysfunction. In mice, inhibiting NNMT can reduce fat accumulation and improve metabolic markers. Specific 5A1MQ experiments have reported improvements in body composition, glucose tolerance, insulin sensitivity, hyperinsulinemia, and fatty-liver pathology. But the research-market story skips a rather important step: there is currently no established human clinical evidence showing that 5-Amino-1MQ causes weight loss in people. This remains overwhelmingly a preclinical research compound.
What Is 5-Amino-1MQ?
NNMT stands for: Nicotinamide N-methyltransferase. The enzyme catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide, producing 1-methylnicotinamide (1-MNA). NNMT therefore sits at an interesting intersection between: • NAD+ precursor metabolism • Methyl-group metabolism • Energy regulation • Adipose biology Researchers observed that NNMT expression is altered in metabolic disease and began investigating whether inhibiting the enzyme could change energy metabolism. 5-Amino-1MQ emerged from medicinal-chemistry programs developing selective, membrane-permeable NNMT inhibitors.
What Are Researchers Studying?
Obesity and adiposity
This is the main reason 5A1MQ became popular. NNMT inhibition in diet-induced obese mice has been associated with: • Reduced body-weight gain • Reduced fat mass • Smaller adipocytes • Reduced lipogenesis • Improved metabolic function A 2024 study specifically examining 5A1MQ found dose-dependent limitation of body-weight and fat-mass gain during 28 days of treatment in diet-induced obese mice. That is meaningful preclinical evidence. It is not human weight-loss evidence.
Insulin sensitivity
5A1MQ-treated obese mice showed improved: • Glucose tolerance • Insulin sensitivity • Hyperinsulinemia in the 2024 study. Other NNMT inhibitors have produced similar effects in metabolic-disease models, strengthening the case that NNMT itself is a biologically interesting metabolic target. But: NNMT inhibition as a promising drug target ≠ 5A1MQ being a proven metabolic therapy.
Fatty liver
5A1MQ has also been investigated in diet-induced fatty-liver pathology. In obese mice, treatment reduced: • Liver weight • Hepatic triglycerides • Steatosis • Macrophage infiltration alongside broader improvements in metabolic function. This makes NNMT inhibition interesting in the broader metabolic-dysfunction spectrum rather than merely as a weight-loss mechanism. There is not yet adequate evidence to describe 5A1MQ as a treatment for human fatty-liver disease.
NAD+ metabolism
NNMT uses nicotinamide, which also participates in the NAD+ salvage pathway. Consequently, NNMT activity can influence the cellular availability and handling of NAD+-related metabolites. Experimental NNMT inhibition has been associated with increased intracellular NAD+ under some conditions. This is one reason 5A1MQ sometimes gets marketed alongside NAD+ and longevity compounds. However: 5A1MQ is not NAD+. And: NNMT inhibition does not simply equal “boosting NAD+.” The underlying metabolic network is substantially more complicated.
SAM and methyl metabolism
NNMT consumes SAM, an important cellular methyl donor. Researchers have therefore proposed that NNMT inhibition can influence both NAD-related metabolism and SAM-dependent methylation capacity. In experimental adipocytes, selective NNMT inhibitors increased intracellular NAD+ and SAM while reducing lipogenesis. This dual relationship is one of the more interesting aspects of NNMT biology.
Diet and metabolic adaptation
Researchers have also studied 5A1MQ alongside dietary interventions. In obese mice switched from an obesity-promoting diet to a lower-fat diet, adding 5A1MQ produced substantially greater reductions in adiposity than dietary change alone under the experimental conditions. That study also investigated changes in the gut microbiome. Again, this is a mouse experiment—not evidence for a particular human diet/5A1MQ regimen.
How Does It Work?
The proposed chain is: 5-Amino-1MQ ↓ NNMT inhibition ↓ reduced conversion of nicotinamide to 1-MNA ↓ changes in nicotinamide / NAD+ metabolism and changes in SAM / methyl-donor metabolism ↓ altered adipocyte and metabolic signaling. Experimental NNMT inhibition has been associated with: • Reduced lipogenesis • Increased NAD+ • Increased SAM • Improved insulin sensitivity • Altered adipose metabolism But metabolic networks are interconnected. It is too simplistic to say: "5A1MQ blocks the enzyme that prevents fat burning."
What Does the Research Show?
Human research
Direct controlled human evidence for 5-Amino-1MQ is currently lacking. There are human data concerning: • NNMT expression • NNMT biomarkers • Obesity • Diabetes • Cancer • Metabolic disease But those studies investigate the biological target, not necessarily administration of 5A1MQ. That distinction is essential.
Animal research
This is the strongest efficacy evidence. 5A1MQ has been investigated primarily in obese mice. Reported effects include: • Reduced adiposity • Reduced body-weight gain • Improved glucose tolerance • Improved insulin sensitivity • Reduced hyperinsulinemia • Reduced hepatic steatosis A 2024 study also characterized its mouse pharmacokinetics and tissue distribution following multiple routes of administration.
In-vitro research
Cellular experiments helped establish the mechanism of NNMT inhibitors. Researchers have examined: • NNMT inhibition • 1-MNA production • NAD+ • SAM • Lipogenesis • Adipocyte metabolism • Compound selectivity Medicinal-chemistry studies have also characterized the structure-activity relationships required for selective NNMT inhibition.
Notable Studies
Selective and Membrane-Permeable Small Molecule Inhibitors of Nicotinamide N-Methyltransferase Reverse High Fat Diet-Induced Obesity in Mice
animalResearchers developed selective methylquinolinium NNMT inhibitors and demonstrated reductions in intracellular 1-MNA alongside increases in NAD+ and SAM and reduced lipogenesis. Systemic NNMT inhibition in diet-induced obese mice significantly reduced body weight and white-adipose mass without reducing total food intake.
Limitations: Preclinical research. Results from mouse obesity models do not establish human weight-loss efficacy or safety.
View publication →Nicotinamide N-Methyltransferase Inhibition Mitigates Obesity-Related Metabolic Dysfunction
animalResearchers specifically evaluated 5A1MQ for 28 days. Treatment dose-dependently limited body-weight and fat-mass gains, improved glucose tolerance and insulin sensitivity, reduced hyperinsulinemia, and improved hepatic steatosis and inflammatory pathology. The investigators also characterized plasma pharmacokinetics and tissue distribution in mice.
Limitations: Mouse study. It cannot establish human weight-loss efficacy, safe human exposure, or long-term safety.
View publication →Reduced Calorie Diet Combined With NNMT Inhibition Establishes a Distinct Microbiome in DIO Mice
animalResearchers combined dietary change with 5-amino-1-methylquinolinium treatment. NNMT inhibition plus dietary intervention produced pronounced reductions in body weight and adiposity, while the investigators also characterized changes in gut microbial communities.
Limitations: Small animal experiment. Microbiome associations are particularly difficult to translate directly from mice to humans.
View publication →What We Still Don't Know
• Whether 5A1MQ causes weight loss in humans • Human pharmacokinetics • Human bioavailability • Safe human exposure • Long-term safety • Effects of chronic NNMT inhibition • Whether mouse improvements in insulin sensitivity translate to humans • Whether fatty-liver findings translate clinically • Effects on human methylation biology • Effects on NAD+ metabolism during chronic exposure • Whether inhibiting NNMT could have unwanted effects in tissues where NNMT serves useful physiological roles • Reproductive safety • Cardiovascular safety • Cancer-related implications of chronic NNMT manipulation • Whether research-market material matches compounds used in published experiments
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the 5-Amino-1MQ research with you.
Get the Aminodex 5-Amino-1MQ Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Neelakantan H, et al. Selective and Membrane-Permeable Small Molecule Inhibitors of Nicotinamide N-Methyltransferase Reverse High Fat Diet-Induced Obesity in Mice.
- Nicotinamide N-Methyltransferase Inhibition Mitigates Obesity-Related Metabolic Dysfunction. 2024.
- Neelakantan H, Wang HY, Vance V, et al. Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase. Journal of Medicinal Chemistry. 2017.
Supplier Listings
Disclosure: The owner of Aminodex operates the supplier(s) marked below. These listings are promotion for businesses we own, not independent recommendations. Read our disclosures.